TL;DR
US midterm voters show strong support for Pepfar, with 74% backing funding for the HIV/Aids relief initiative. The Trump administration's proposed cuts may negatively impact candidates in the upcoming elections.
US midterm voters overwhelmingly support Pepfar, an initiative to end HIV/Aids that also has strengthened health systems against other infectious disease threats but has come under fire from the Trump administration.
About three in four (74%) of likely voters in the US midterm elections say they support funding the US President’s Emergency Plan for AIDS Relief (Pepfar), with voters more likely to back candidates who support Pepfar, according to a recent poll. Four in five (80%) of the voters said there is a moral argument for supporting lifesaving treatment for people at risk for or living with HIV/Aids, regardless of their personal choices.
Among voters, “it’s going to be seen positively if Republicans or Democrats pursue Pepfar”, said Jennifer Kates, senior vice-president and director of the global and public health policy program at KFF, a health non-profit. These results align with other surveys showing the bipartisan popularity of the program, and a growing sense that the Trump administration is abdicating its international leadership even as outbreaks spiral out of control.
First created by George W Bush in 2003, Pepfar has long enjoyed Republican leadership and bipartisan support. In recent months, Congress has repeatedly moved to preserve the program, but it is now essentially being replaced with individual agreements with countries that include but aren’t heavily focused on HIV prevention and treatment.
According to a 5 May announcement, the state department will keep nearly all of the funding intended for Pepfar, instead of splitting it with the US Centers for Disease Control and Prevention. The CDC would only receive 7% of the funds – $150m, instead of a potential $2bn.
It mirrors the dissolution of the US Agency for International Development (USAID) and its absorption into the state department last year, said Asia Russell, executive director of Health Gap, an HIV/Aids treatment advocacy organization: “USAID, that’s already gone, right? That’s like the East Wing of the White House cut off, essentially. Now they want to cut off the West Wing, too.”
Domestically, the president’s proposed budget also included a $1.6bn cut to HIV funding – mainly on prevention work.
The continued support for Pepfar, even against a backdrop of economic instability, shows “America’s compassion”, said Michael Vazquez, founder and managing partner of the Maiden Group, which conducted the polling. “There is a huge disconnect between some policymakers and the American public when you see that folks are as committed as ever to seeing Pepfar continue.”